Update on the utility of prognostic biomarkers in ovarian cancer.
There is considerable interest in the gynecologic cancer community for the development of biomarkers that will be of utility in routine management of women with advanced ovarian cancer. However, at the present time, there remains limited evidence for the usefulness of any such test other than the serum cancer antigen (CA)-125 level, employed to monitor the course of disease in response to treatment or during periods of observation.
Department of Gynecologic Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77005 USA.
Maurie
M
Markman